Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 May 19:12:55-66.
doi: 10.2147/AHMT.S303456. eCollection 2021.

Natural History and Disease Burden of Neurofibromatosis Type 1 with Plexiform Neurofibromas: A Systematic Literature Review

Affiliations
Review

Natural History and Disease Burden of Neurofibromatosis Type 1 with Plexiform Neurofibromas: A Systematic Literature Review

Catherine Copley-Merriman et al. Adolesc Health Med Ther. .

Abstract

Neurofibromatosis type 1 (NF1) is an incurable genetic condition that frequently includes the development of plexiform neurofibromas (PNs) in patients. A systematic literature review was conducted to identify data on the natural history, disease burden, and treatment patterns among patients diagnosed with NF1 and PN, as well as to identify evidence gaps in these areas. MEDLINE and MEDLINE In-Process, Embase, and Cochrane Library Searches were searched using predefined terms. Potential references underwent two phases of screening by two independent researchers. A total of 39 references focusing on populations of patients with both NF1 and PN were included in this review. The wide range of PN-related complications creates a substantial quality-of-life (QOL) burden for patients, including pain, social functioning, physical function impact, stigma, and emotional distress. The severe burden of NF1 with PN on the QOL of patients demonstrates the high unmet need for an effective treatment option that can reduce tumor burden and improve QOL. The heterogeneity of measurement tools used to evaluate QOL and the gap in data evaluating the health economic burden of PN should be the focus of future research.

Keywords: natural history; neurofibromatosis type 1; plexiform neurofibromas; quality of life; review.

PubMed Disclaimer

Conflict of interest statement

CCM and MJ are full-time employees of RTI Health Solutions, an independent nonprofit research organization, which received funding pursuant to a contract from Merck to conduct the study, which is the subject of this manuscript. XY is an employee of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA, and holds shares in Merck & Co., Inc., Kenilworth, NJ, USA stock. SSS was an employee of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA, at the time the study was conducted. SA and HKY are employees of AstraZeneca and hold shares in AstraZeneca stock.

Figures

Figure 1
Figure 1
PRISMA diagram.

References

    1. Genetics Home Reference. Neurofibromatosis type 1. Available from: https://ghr.nlm.nih.gov/condition/neurofibromatosis-type-1#statistics.. Accessed May 3, 2020.
    1. Menon AG, Gusella JF, Seizinger BR. Progress towards the isolation and characterization of the genes causing neurofibromatosis. Cancer Surv. 1990;9(4):689–702. - PubMed
    1. Menon AG, Gusella JF, Seizinger BR. Progress toward the isolation and characterization of the genes causing neurofibromatosis. Brain Pathol. 1990;1(1):33–40. doi:10.1111/j.1750-3639.1990.tb00636.x - DOI - PubMed
    1. Monroe CL, Dahiya S, Gutmann DH. Dissecting clinical heterogeneity in neurofibromatosis type 1. Annu Rev Pathol. 2017;12:53–74. doi:10.1146/annurev-pathol-052016-100228 - DOI - PubMed
    1. National Institutes of Health Consensus Development Conference. Neurofibromatosis. Conference statement. Arch Neurol. 1988;45(5):575–578. doi:10.1001/archneur.1988.00520290115023 - DOI - PubMed